Express News | Adial Pharmaceuticals FY 2024 GAAP EPS $(2.72) Beats $(2.97) Estimate
10-K: FY2024 Annual Report
Adial Pharmaceuticals Expects Cash to Fund Operations Into 2H of 2025
Adial Pharma Believes Existing Cash and Cash Equivalents Will Fund Oper Expenses Into 2H
Express News | Adial Pharmaceuticals FY Net Income USD -13.2 Million
Adial Pharmaceuticals Shares Are Trading Higher After the Company Announced It Received FDA Feedback for Its Vitro Bridging Strategy of AD04 and Will Proceed to Manufacture Clinical Supplies for Its Upcoming Phase 3 Clinical Trial.
Express News | Adial Pharmaceuticals Receives Positive Response From FDA Meeting Regarding Proposed in Vitro Bridging Strategy for Ad04
Adial Pharmaceuticals Receives Positive Response From FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04
EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'New Patent Expands Patent Estate Covering Adial's Unique Molecular Genetic Approach to Diagnosing and Potentially Treating Alcohol and Drug Dependence'
Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Awarded New U.S Patent Covering Genotype-Specific Treatment Of Opioid -Related Disorders
EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder
Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Safety and Tolerability Consistent With Ondansetron's Extensive Human Use Experience'
Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Adial's Formulation Exhibited Predictable Bioavailability Relative to the Reference Standard; Near-micro Doses Exhibited Dose Proportionality in Pharmacokinetic Exposure, and No Food Effect'
Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Completion Enables the End-of-Phase 2 (EOP2) Interaction With the FDA on the Design of the Phase 3 Program and Is Expected to Facilitate Ongoing Partnership Discussions'
Adial Pharmaceuticals Focuses on Strategic Growth Initiatives
Adial Pharmaceuticals' New Purchase Agreement With Alumni Capital
Express News | Adial Pharmaceuticals Inc - Can Sell up to $10 Million in Shares